Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer - Wikidata - awgldk - TriplyDB

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

http://www.wikidata.org/entity/Q24540270

about

High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area A common missense variant in BRCA2 predisposes to early onset breast cancer.Prevalence of the most frequent BRCA1 mutations in Polish population Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs BRCA1 4153delA founder mutation in Russian ovarian cancer patients Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.BRCA1 founder mutations compared to ovarian cancer in Belarus.A high proportion of founder BRCA1 mutations in Polish breast cancer families.Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy Modifiers of risk of hereditary breast and ovarian cancer.Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing.Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece.Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.Hereditary breast-ovarian cancer syndrome in Russia.Expression of TopBP1 in hereditary breast cancer BRCA Testing in Serbia and Montenegro.Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing DNA and RNA analyses in detection of genetic predisposition to cancer.When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans.Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.BRCA2 gene mutations in families with aggregations of breast and stomach cancers.Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

P2860

Q24813558-FF764E51-2A8F-4E1F-A779-5E4D2AA12D6C Q25257499-CC16C4BF-322A-4040-B309-FC0AA3E0556D Q28390186-A442DE78-AAA6-42CA-9B7C-6541896797B3 Q33289529-DF165EE0-196E-45C6-8C39-2BA1204827F6 Q33321039-7E3C66D7-0456-43BF-8C20-462D38DB8B28 Q33327308-0142FE78-D650-430F-A8CB-623BEDA0B77A Q33419708-DD3937B2-07F5-43BC-B0BE-EA29400E494A Q33484437-1428F1CE-821B-49B4-B5DD-C4AC0E5C7668 Q33722537-0A8A4E16-F5CD-4122-8544-B516FD6A6829 Q33722598-1EF3351D-09BE-449D-B37C-5019E2DD4A81 Q33761201-FFED5864-E12E-4A93-BE75-E637C54F0563 Q33842311-84927DED-BE08-4453-8E85-9DF637FC373C Q34029011-88E385C8-1F1B-47F5-961C-2430F4564853 Q34059765-3CDC5729-3AFC-4C14-B361-16B3875F9658 Q34185187-03D74D93-9F02-4699-9DEC-1CC7BDBC4F48 Q34548008-88D9344E-CAAE-41D3-9B70-0A1BCD612DCA Q35060014-AECE056D-AB7B-4F98-A4EE-21611BA0FC7B Q35084790-6AB82C69-4945-442E-BCCF-DF1A9F8DD82E Q35546258-C22C48A0-6E69-4D85-B3B4-E6E1858E2A91 Q35619211-B1748B3A-4D07-4EA7-A753-9511479AE493 Q35830539-B6CDDFA4-1C15-4277-B01E-246F50CDD4C7 Q35867279-73109B3B-A046-470C-9A14-30D0A268F4B4 Q35916613-D991B77B-5F2A-476C-BD63-6D719FCFF626 Q35944416-FA05BABF-8041-43EA-AA9B-28725542A362 Q35981641-FCF61ED8-02AA-4634-AF98-F1CE47641FFC Q36108151-5F052FF8-4C8E-4BFE-A7C7-9C8A0EF6E969 Q36117690-A4F21A28-8DC4-44C4-A1AE-2AAE941A5A44 Q36315223-19C490A4-781C-4582-842D-5EB446FEFF3E Q36394369-DB577021-B017-4483-B9C3-4B83D11AD22F Q36446316-A83D677D-ED56-46E0-AB3E-C6AB0433CE2B Q36466697-928C0462-E5D5-4BEB-AD5E-12EB021CCD0A Q36474986-3A387E02-CB31-4D08-819D-9EEC58FDF2C4 Q36552174-E23323A8-B120-4839-B400-8E18E05C0EA8 Q36583892-1D073306-CCAC-4C18-9602-826C0945B8ED Q36634141-EE0CF95C-1011-4587-90AD-7CD85652E3EC Q36646182-B55F98CD-ACC3-4ED0-B105-151AEDF695FB Q36660863-03E0F461-CFC9-448F-9B59-E215DD10C98E Q36700472-61B25628-766C-475D-9687-70B05E384194 Q36849117-E4B8827B-99EE-4019-882A-2C27A098AAF7 Q36924418-209EED47-2D09-4C96-89D6-4E3AD4B6B575

P2860

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

http://www.wikidata.org/entity/Q24540270

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@ast

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@en

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@nl

type

label

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@ast

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@en

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@nl

prefLabel

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@ast

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@en

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@nl

P1433

Q24540270-E0488803-CE45-4147-B0CF-EABE450CB7F0

P1476

Q24540270-6E5A0198-2B2A-4E65-BD78-DBB3F0F8492A

P2093

Q24540270-07F0FFF3-C174-48C4-BAA5-73865E499803

Q24540270-383827CA-74C0-4223-970E-CC6D9C5FD564

Q24540270-A88B2231-32A6-493B-BBEF-32E82FE1B095

Q24540270-C617D7B0-6D54-486D-A4B2-46D8829E8B1B

Q24540270-C67F8529-8463-4E6C-A7C2-3D0C14D8777E

Q24540270-C7CD98DF-9724-422D-A244-CCF3430045A7

Q24540270-FB39FE9B-BE4E-4878-B3D4-CBB7180193C7

P2860

Q24540270-0D5131D3-4551-4025-9337-8FFAE2496E73

Q24540270-0EC078BB-1504-499E-B8B4-A55EDCA02622

Q24540270-113741DE-93A4-44F8-9D56-6EE66902761E

Q24540270-12D0AC70-23E7-44ED-931E-3872226E7AE4

Q24540270-2A8DB54D-E5A4-4345-AEAB-3FE680D67C97

Q24540270-2EC8ABFC-33EA-468F-9DEF-6F92B3D10FE4

Q24540270-3A555CE5-3083-4D4F-ADC1-92CC83C6B225

Q24540270-46CC17FE-3507-4CDA-B799-D2B82A7F5FE5

Q24540270-54463D4F-88AA-4393-BD7B-24D521B91EF0

Q24540270-5CD63E1B-473E-4E22-B73C-75B2F715E3BB

P304

Q24540270-50EE7DA5-DABB-456F-A134-CEA33DBD5DCC

P31

Q24540270-2D047599-ECD5-4DDD-8027-8ECC9AFB1175

P356

Q24540270-9C3B4045-0681-4E6E-A296-C54344EF9EA3

P407

Q24540270-F48E51FA-A27D-4DCB-B48E-FA395854B5DC

P433

Q24540270-B5D3EEE9-A4BD-40A6-84E0-B836526DED22

P478

Q24540270-7670E8FD-4660-4B82-B550-710A8F67F016

P50

Q24540270-00C9AA90-7F87-4C24-9735-E6D646FD0BD0

Q24540270-117FC634-5FAC-4282-B7B2-167925886946

Q24540270-D98B56BE-46B5-4971-9887-CA61BBAE6B82

Q24540270-F2E7710B-7888-4342-9212-191E82974144

Q24540270-FB9597E9-35D3-442D-AAF0-1693DA19BB0F

P577

Q24540270-4DFF2FBD-56D9-4665-8469-D05B3BDCB5DC

P5875

Q24540270-130CD25B-5FCF-413E-8065-48981D4924B6

P698

Q24540270-88076F0E-0286-4CDE-8928-2955C1C31B46

P921

Q24540270-D6AF6F69-1214-4EA5-A8FD-55703D4427DC

P932

Q24540270-3A271B75-9338-4744-920A-4BD45B059D4D

P356

P1433

American Journal of Human Genetics

P1476

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

@en

P2093

Bebenek M

http://www.w3.org/2001/XMLSchema#string

Fischer-Maliszewska L

http://www.w3.org/2001/XMLSchema#string

Gronwald J

http://www.w3.org/2001/XMLSchema#string

Grzybowska E

http://www.w3.org/2001/XMLSchema#string

Górski B

http://www.w3.org/2001/XMLSchema#string

Huzarski T

http://www.w3.org/2001/XMLSchema#string

Pluzańska A

http://www.w3.org/2001/XMLSchema#string

P2860

DNA sequencing with chain-terminating inhibitors

BRCA1 mutations in Ashkenazi Jewish women

Study of a single BRCA2 mutation with high carrier frequency in a small population

Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia

A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

Identification of the breast cancer susceptibility gene BRCA2

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

P304

1963-1968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/302922

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Steven A. Narod

Anna Jakubowska

Janusz Menkiszak

P577

2000-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12529691

http://www.w3.org/2001/XMLSchema#string

P698

10788334

http://www.w3.org/2001/XMLSchema#string

P921

P932

1378051

http://www.w3.org/2001/XMLSchema#string